JP2022526978A - ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 - Google Patents

ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 Download PDF

Info

Publication number
JP2022526978A
JP2022526978A JP2021559092A JP2021559092A JP2022526978A JP 2022526978 A JP2022526978 A JP 2022526978A JP 2021559092 A JP2021559092 A JP 2021559092A JP 2021559092 A JP2021559092 A JP 2021559092A JP 2022526978 A JP2022526978 A JP 2022526978A
Authority
JP
Japan
Prior art keywords
polypeptide
lysate
gram
activity
lytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526978A5 (https=
Inventor
レイモンド シューフ
Original Assignee
コントラフェクト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コントラフェクト コーポレイション filed Critical コントラフェクト コーポレイション
Publication of JP2022526978A publication Critical patent/JP2022526978A/ja
Publication of JP2022526978A5 publication Critical patent/JP2022526978A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021559092A 2019-04-05 2020-04-03 ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 Pending JP2022526978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830207P 2019-04-05 2019-04-05
US62/830,207 2019-04-05
PCT/US2020/026681 WO2020206327A1 (en) 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Publications (2)

Publication Number Publication Date
JP2022526978A true JP2022526978A (ja) 2022-05-27
JP2022526978A5 JP2022526978A5 (https=) 2023-03-27

Family

ID=72667504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559092A Pending JP2022526978A (ja) 2019-04-05 2020-04-03 ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体

Country Status (11)

Country Link
US (1) US20220160843A1 (https=)
EP (1) EP3946609A4 (https=)
JP (1) JP2022526978A (https=)
KR (1) KR20210148320A (https=)
CN (1) CN114040773A (https=)
AU (1) AU2020256258A1 (https=)
BR (1) BR112021019430A2 (https=)
CA (1) CA3136126A1 (https=)
IL (1) IL286941A (https=)
MX (1) MX2021012166A (https=)
WO (1) WO2020206327A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24750B1 (es) * 2020-11-19 2025-06-11 Centro De Investig Y Desarrollo De Medicamentos Cidem Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CN116200418A (zh) * 2021-12-01 2023-06-02 华南农业大学 一种筛选铜绿假单胞菌LasR基因调控网络未知基因突变体的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527378A (ja) * 2015-09-17 2018-09-20 コントラフェクト コーポレイション グラム陰性菌に対して活性を有する溶解素ポリペプチド
JP2021519083A (ja) * 2018-03-29 2021-08-10 コントラフェクト コーポレイション 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用
JP2021533728A (ja) * 2018-08-23 2021-12-09 コントラフェクト コーポレイション 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701777B2 (ja) * 2009-02-06 2015-04-15 テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
BR112020011433A2 (pt) * 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) * 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527378A (ja) * 2015-09-17 2018-09-20 コントラフェクト コーポレイション グラム陰性菌に対して活性を有する溶解素ポリペプチド
JP2018534247A (ja) * 2015-09-17 2018-11-22 コントラフェクト コーポレイション 肺サーファクタントによって阻害される抗生物質の肺サーファクタントの存在下における抗細菌活性を回復/増加させるための溶解素の使用
JP2021519083A (ja) * 2018-03-29 2021-08-10 コントラフェクト コーポレイション 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用
JP2021533728A (ja) * 2018-08-23 2021-12-09 コントラフェクト コーポレイション 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Bacteriophage-Derived Lysins can be Engineered to Exert a Rapid and Potent Bactericidal Effect Again", AUSTRALIAN SOCIETY FOR MICROBIOLOGY (ASM) CONFERENCE 2018, SUNDAY-HMB LB14, JPN6024008058, 2018, ISSN: 0005426251 *
"Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against Pseudomonas aeruginosa", ANTIMICROBIAL PEPTIDES GORDON RESEARCH CONFERENCE, JPN6024008057, 1 March 2019 (2019-03-01), ISSN: 0005426252 *

Also Published As

Publication number Publication date
MX2021012166A (es) 2021-11-03
CA3136126A1 (en) 2020-10-08
EP3946609A1 (en) 2022-02-09
EP3946609A4 (en) 2023-05-03
US20220160843A1 (en) 2022-05-26
BR112021019430A2 (pt) 2021-11-30
KR20210148320A (ko) 2021-12-07
AU2020256258A1 (en) 2021-11-04
WO2020206327A1 (en) 2020-10-08
IL286941A (en) 2021-10-31
CN114040773A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
US12121568B2 (en) Identification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa
JP7029805B2 (ja) グラム陰性菌に対して活性を有する溶解素ポリペプチド
CN112368376A (zh) 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210147498A1 (en) Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in pulmonary surfactant and biofilms
JP2021513865A (ja) 修飾PlySs2溶解素及びその使用
Kumar Natural peptides and their synthetic congeners acting against Acinetobacter baumannii through the membrane and cell wall: latest progress
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
WO2020093057A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾PlySs2溶解素及び抗生物質の組合せ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001